ACETAMINOPHEN AND IBUPROFEN

ACETAMINOPHEN AND IBUPROFEN was reported 220 times

These side effects are most commonly reported by patients taking ACETAMINOPHEN AND IBUPROFEN:

# Side effect Count
0 DRUG INEFFECTIVE 47
1 DRUG EFFECTIVE FOR UNAPPROVED INDICATION 30
2 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 27
3 DRUG EFFECT LESS THAN EXPECTED 15
4 UNDERDOSE 13
5 OVERDOSE 10
6 INCORRECT DOSE ADMINISTERED 9
7 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 8
8 HYPERSENSITIVITY 8
9 OFF LABEL USE 7
10 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 6
11 DRUG HYPERSENSITIVITY 5
12 MALAISE 4
13 SOMNOLENCE 4
14 DIARRHOEA 3
15 FATIGUE 3
16 INJECTION SITE BRUISING 3
17 OROPHARYNGEAL PAIN 3
18 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 3
19 ABDOMINAL DISCOMFORT 2
20 ABDOMINAL PAIN UPPER 2
21 ANXIETY 2
22 ASTHENIA 2
23 CARDIAC FAILURE 2
24 CONSTIPATION 2
25 DEFAECATION URGENCY 2
26 DRUG DEPENDENCE 2
27 DYSPNOEA 2
28 EXTRA DOSE ADMINISTERED 2
29 FEELING ABNORMAL 2
30 GASTROENTERITIS VIRAL 2
31 HEADACHE 2
32 INCORRECT PRODUCT ADMINISTRATION DURATION 2
33 INSOMNIA 2
34 INTENTIONAL PRODUCT USE ISSUE 2
35 PRODUCT USE IN UNAPPROVED INDICATION 2
36 SINUSITIS 2
37 THERAPEUTIC PRODUCT EFFECT DECREASED 2
38 THERAPEUTIC PRODUCT EFFECT VARIABLE 2
39 THROAT IRRITATION 2
40 VOMITING 2
41 ABDOMINAL PAIN 1
42 ACUTE KIDNEY INJURY 1
43 ARTHRALGIA 1
44 BLOOD GLUCOSE INCREASED 1
45 BRAIN OEDEMA 1
46 CARDIAC DISORDER 1
47 CATHETER SITE PAIN 1
48 CHEST PAIN 1
49 CHRONIC RESPIRATORY FAILURE 1
50 CONDITION AGGRAVATED 1
51 CORNEAL PERFORATION 1
52 CORONAVIRUS INFECTION 1
53 COUGH 1
54 COVID-19 1
55 CYSTITIS 1
56 DEATH 1
57 DEPRESSION 1
58 DEVICE ISSUE 1
59 DIAPHRAGMATIC PARALYSIS 1
60 DISEASE RECURRENCE 1
61 DIZZINESS 1
62 DRUG SCREEN POSITIVE 1
63 DYSBIOSIS 1
64 DYSGEUSIA 1
65 DYSPEPSIA 1
66 EXPIRED PRODUCT ADMINISTERED 1
67 FEELING DRUNK 1
68 FLATULENCE 1
69 GASTRITIS 1
70 GASTROINTESTINAL DISORDER 1
71 HAEMATOCHEZIA 1
72 HAEMORRHAGE 1
73 HEPATIC FAILURE 1
74 HOSPITALISATION 1
75 HOT FLUSH 1
76 HYPERTENSION 1
77 INCREASED NEED FOR SLEEP 1
78 INFLUENZA LIKE ILLNESS 1
79 INJECTION SITE ERYTHEMA 1
80 INJECTION SITE PRURITUS 1
81 INJECTION SITE SWELLING 1
82 INJECTION SITE WARMTH 1
83 INTENTIONAL DOSE OMISSION 1
84 INTENTIONAL OVERDOSE 1
85 KERATITIS 1
86 KIDNEY INFECTION 1
87 LIVER DISORDER 1
88 LIVER INJURY 1
89 MOBILITY DECREASED 1
90 MUSCULOSKELETAL DISCOMFORT 1
91 NASAL CONGESTION 1
92 NASOPHARYNGITIS 1
93 NAUSEA 1
94 NOCTURIA 1
95 OBLITERATIVE BRONCHIOLITIS 1
96 PAIN 1
97 PALPITATIONS 1
98 PARAESTHESIA 1
99 PERICARDITIS 1
100 PNEUMOMEDIASTINUM 1
101 PNEUMONIA 1
102 PNEUMOTHORAX 1
103 PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE 1
104 PRODUCT AFTER TASTE 1
105 PRODUCT DOSE OMISSION ISSUE 1
106 PRODUCT FORMULATION ISSUE 1
107 PRODUCT QUALITY ISSUE 1
108 PRODUCT SOLUBILITY ABNORMAL 1
109 PRODUCT USE COMPLAINT 1
110 PRURITUS 1
111 PSEUDOMONAS INFECTION 1
112 PSORIATIC ARTHROPATHY 1
113 PYREXIA 1
114 RASH 1
115 RESPIRATORY DISORDER 1
116 RESTLESS LEGS SYNDROME 1
117 RHINORRHOEA 1
118 ROTATOR CUFF SYNDROME 1
119 SENSITIVE SKIN 1
120 SKIN DISCOLOURATION 1
121 STEVENS-JOHNSON SYNDROME 1
122 SURGERY 1
123 THERAPEUTIC PRODUCT EFFECT DELAYED 1
124 THERAPEUTIC RESPONSE UNEXPECTED 1
125 ULCER HAEMORRHAGE 1
126 ULCERATIVE KERATITIS 1
127 URINARY TRACT INFECTION 1
128 URTICARIA 1